Amgen Reacquires All Product Rights To Prolia® (denosumab), XGEVA® (denosumab) And Vectibix® (panitumumab) From GSK In 48 Countries
Adds Product Rights and Sales in Key Global Expansion Countries
THOUSAND OAKS, Calif., Dec. 14, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions throughout the world. The agreement involves key expansion markets for Amgen including Brazil, China, Colombia, Hong Kong, Israel, Singapore, South Korea, Taiwan and Thailand.
GSK has held select regional rights to Proli...
Source: Amgen News Release - December 14, 2015 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Denosumab Boosts Survival, Not Just Bones, in Breast CancerDenosumab Boosts Survival, Not Just Bones, in Breast Cancer
New results from the ABSCG-18 trial fuel the argument for bone-strengthening cancer therapies. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
ABCSG 18: Monoclonal antibody increases disease-free survival in breast cancer
Giving a monoclonal antibody (denosumab) as adjuvant therapy with aromatase inhibitors in postmenopausal, hormone-receptor-positive breast cancer patients reduces the relapse rate by 18%. This is the central finding of the ABCSG 18 breast cancer study regarding disease-free survival. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 9, 2015 Category: Science Source Type: news
Breast Cancer Drugs Battle Disease’s Return
Xeloda lowered risk by a third, while Xgeva lowered chances by 18 percent, researchers report (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 9, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Oncology, Pharmacy, Research, News, Source Type: news
Breast Cancer Drugs Battle Disease's Return
Afinitor lowered risk by a third, while Xgeva lowered chances by 18 percent, researchers report (Source: WebMD Health)
Source: WebMD Health - December 9, 2015 Category: Consumer Health News Source Type: news
Breast Cancer Drugs Battle Disease's Return
Afinitor lowered risk by a third, while Xgeva lowered chances by 18 percent, researchers report (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - December 9, 2015 Category: Cancer & Oncology Source Type: news
Denosumab Boosts Bone Quality in RA (CME/CE)
(MedPage Today) -- Fewer erosions and improvements in bone density observed (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 29, 2015 Category: Primary Care Source Type: news
Decade of Data on Denosumab for Osteoporosis ReassuringDecade of Data on Denosumab for Osteoporosis Reassuring
The 10-year results of the FREEDOM extension trial with denosumab to treat osteoporosis in postmenopausal women are "very encouraging," says one expert. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 15, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Teriparatide to Denosumab Switch Helpful in OsteoporosisTeriparatide to Denosumab Switch Helpful in Osteoporosis
In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research. Reuters Health Information (Source: Medscape ObGyn and Womens Health Headlines)
Source: Medscape ObGyn and Womens Health Headlines - July 15, 2015 Category: OBGYN Tags: Orthopaedics News Source Type: news
Drug approved to treat osteoporosis shows promise in pre-clinical diabetes research
A drug commonly used to treat osteoporosis in humans also stimulates the production of cells that control insulin balance in diabetic mice, researchers have found. While other compounds have been shown to have this effect, the drug (Denosumab) is already FDA approved and could more quickly move to clinical trials as a diabetes treatment. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 18, 2015 Category: Science Source Type: news
Prolia Plus Biologic Deemed Safe in RA (CME/CE)
(MedPage Today) -- No increase in hospitalization for infections seen with denosumab. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - March 3, 2015 Category: Geriatrics Source Type: news
Denosumab cost effective in women with osteoporosis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2015 Category: Drugs & Pharmacology Source Type: news
Denosumab an Effective Alternative to BisphosphonatesDenosumab an Effective Alternative to Bisphosphonates
Physicians should consider the monoclonal antibody denosumab as an effective alternative osteoporosis treatment for postmenopausal women who find it difficult to adhere to oral bisphosphonates, new research shows. Reuters Health Information (Source: Medscape ObGyn and Womens Health Headlines)
Source: Medscape ObGyn and Womens Health Headlines - January 5, 2015 Category: OBGYN Tags: Diabetes & Endocrinology News Source Type: news
Study by UCLA scientists reveals new findings about cause of lesions around jaw bone
This study was highlighted in “This Month in AJP” in the November issue and featured as the Editor’s Choice article, which is available to the science community. This paper was also designated for journal-based Continuing Medical Education activity sponsored by Accreditation Council for Continuing Medical Education, as well as the American Society of Investigative Pathology and American Society for Clinical Pathology. (Source: UCLA Newsroom: Health Sciences)
Source: UCLA Newsroom: Health Sciences - November 24, 2014 Category: Universities & Medical Training Source Type: news
